Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAJED A KOLEILAT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1922175694
CMS profile
178334
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$8,447.25

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAJED A KOLEILAT

NPI 1922175694 · CMS profile ID 178334

Allopathic & Osteopathic Physicians / Allergy & Immunology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922175694?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922175694?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922175694?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1922175694?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $8,447.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $20.7206/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738688869 CMS
GENZYME CORPORATION $12.6706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744199521 CMS
PFIZER INC. $24.9105/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743453316 CMS
Regeneron Healthcare Solutions, Inc. $19.7305/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724431519 CMS
GlaxoSmithKline, LLC. $22.2305/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738541877 CMS
CSL Behring $13.2305/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728973877 CMS
AstraZeneca Pharmaceuticals LP $20.5905/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736145973 CMS
ALK-Abello, Inc $15.6505/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748138549 CMS
OptiNose US, Inc. $11.9605/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737166197 CMS
AstraZeneca Pharmaceuticals LP $17.7704/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735994529 CMS
AstraZeneca Pharmaceuticals LP $300.0004/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736252513 CMS
AstraZeneca Pharmaceuticals LP $11.2104/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736110091 CMS
AstraZeneca Pharmaceuticals LP $17.5803/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736039421 CMS
AstraZeneca Pharmaceuticals LP $1,350.0003/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735779831 CMS
GENZYME CORPORATION $16.2503/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744199519 CMS
GlaxoSmithKline, LLC. $9.2403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738679659 CMS
AstraZeneca Pharmaceuticals LP $11.5703/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736058015 CMS
CSL Behring $19.4203/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728973853 CMS
AstraZeneca Pharmaceuticals LP $14.0802/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736148667 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.8602/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720551451 CMS
CSL Behring $21.2802/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728973851 CMS
Grifols USA, LLC $21.1102/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750422925 CMS
Regeneron Healthcare Solutions, Inc. $24.0402/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724431515 CMS
GENZYME CORPORATION $18.1302/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744199507 CMS
GlaxoSmithKline, LLC. $17.1402/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738542827 CMS
Novartis Pharmaceuticals Corporation $19.3402/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725980563 CMS
GlaxoSmithKline, LLC. $17.8801/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738837999 CMS
kaleo, Inc. $23.5701/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733175525 CMS
AstraZeneca Pharmaceuticals LP $13.0001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735808133 CMS
CSL Behring $15.7201/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728973841 CMS
Grifols USA, LLC $19.3201/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750418423 CMS
OptiNose US, Inc. $18.1901/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737166157 CMS
AstraZeneca Pharmaceuticals LP $82.1701/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736264435 CMS
BioCryst Pharmaceuticals, Inc. $23.9801/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749719609 CMS
ALK-Abello, Inc $12.8501/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748135095 CMS
PFIZER INC. $13.4801/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743423359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,744.84 121
PY2020 $8,447.25 86
PY2021 $11,770.23 134
PY2022 $6,074.19 136
PY2023 $10,875.95 114
PY2024 $39,987.82 121
PY2025 $21,927.61 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $100,022.72 40
PY2024 Principal investigator $81,746.74 19
PY2023 Principal investigator $105,618.27 27
PY2022 Principal investigator $114,068.39 25
PY2021 Principal investigator $113,740.20 23
PY2020 Principal investigator $60,121.14 30
PY2019 Principal investigator $15,729.05 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $154.00 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048642
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048644
Principal investigator 1 GlaxoSmithKline, LLC. $2,400.00 11/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111062
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 11/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048640
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $428.40 10/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048638
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,958.20 10/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048636
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 10/14/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048634
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $725.60 10/09/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048632
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 09/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048630
Principal investigator 1 GlaxoSmithKline, LLC. $7,192.00 09/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118836
Principal investigator 1 GlaxoSmithKline, LLC. $749.55 09/08/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117552
Principal investigator 1 GlaxoSmithKline, LLC. $76.42 09/03/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111070
Principal investigator 1 GlaxoSmithKline, LLC. $561.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111034
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111040
Principal investigator 1 GlaxoSmithKline, LLC. $106.07 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111047
Principal investigator 1 GlaxoSmithKline, LLC. $806.00 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 08/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048603
Principal investigator 1 GlaxoSmithKline, LLC. $3,275.60 08/01/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111076
Principal investigator 1 GlaxoSmithKline, LLC. $2,062.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117595
Principal investigator 1 GlaxoSmithKline, LLC. $1,620.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117601
Principal investigator 1 GlaxoSmithKline, LLC. $9,109.88 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118824
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 07/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048628
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,650.00 07/23/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549593
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 06/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048626
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $755.00 06/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048624
Principal investigator 1 GlaxoSmithKline, LLC. $2,252.45 06/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117589
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,537.00 06/13/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048622
Principal investigator 1 GlaxoSmithKline, LLC. $869.25 05/05/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,640.15 04/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549591
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,889.50 04/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048620
Principal investigator 1 GlaxoSmithKline, LLC. $965.20 04/04/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117572
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,126.80 03/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048618
Principal investigator 1 GlaxoSmithKline, LLC. $1,092.00 03/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 02/27/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048615
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048672
Principal investigator 1 GlaxoSmithKline, LLC. $1,914.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117560
Principal investigator 1 GlaxoSmithKline, LLC. $915.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,112.80 01/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,327.10 01/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048611
Principal investigator 1 GlaxoSmithKline, LLC. $1,133.35 01/13/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117566